Head, Research & Services
Scleroderma & Reynaud's UK
Fatima Ann Sulaiman is the Head of Research and Services at Scleroderma and Raynaud’s UK (SRUK). SRUK is a patient focused organisation which funds research into scleroderma, a rare orphan auto immune condition. She is leading on the development and implementation of an innovative research strategy which focuses on working collaboratively across industry in order to deliver benefits to patients sooner. A key area of focus is precision medicine and the clinical development of biomarkers which represent large unmet needs for rare disease patients. Previously, she was a senior manager at Cancer Research UK, one of the largest funders of scientific research in the UK. Prior to this, she complete a PhD from the National Institute for Medical Research (now part of the Francis Crick Institute).
Visiting Scientist & Cancer Genomics Consultant
Sanger Institute & NHS
Philip is a physician scientist and precision oncology specialist who operates across the commercial, academic and healthcare sectors. Current projects include clinical implementation of cancer genomics, biomarker discovery and early phase clinical trials, underpinned by a portfolio of relevant academic research.
Associate Director, NICE Diagnostics Assessment Programme
Sarah is the Associate Director of the NICE Diagnostics Assessment programme and has a keen interest in the value of diagnostics to patients and the healthcare system. She is leading on work in genomics, precision medicine and AMR diagnostic technologies at NICE, and is also Chair of the Equality Expert Group for the NICE Centre of Health Technology Evaluation. Prior to joining NICE, Sarah completed a PhD in Biochemistry with the University of Manchester and GlaxoSmithKline, and then worked in research and development at AstraZeneca.
Executive Vice President, Pharma Collaborations & CDx Business
Global CDx Discipline Director
Head, Global Regulatory Affairs, Biomarkers & Diagnostics
Claudia holds the role of Head, Global Regulatory Affairs for the Biomarkers & Diagnostics division at Merck KGaA and is based in Darmstadt. She has previously held roles as the acting head of the hematology branch and as a scientific lead reviewer at the FDA within the Division of Immunology and Hematology Devices (DIHD), Office of In Vitro Diagnostic and Radiological Health (OIR). Claudia received her BS in Biochemistry from Oklahoma State University in 2001 before completing a PhD in genetics from Duke University in 2008.
Chief Commercial Officer
Professor Joanne Hackett is the Chief Commercial Officer at Genomics England and lead member of the Business and Investment Committee. As CCO, Joanne is responsible for Genomics England’s industry engagement strategy by developing, managing and accelerating relationships with commercial organisations − creating opportunities for collaboration both nationally and globally. Joanne is a clinical academic and strategic, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity, Joanne is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne's goal is to contribute in bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics. Genomics England The time for talking about the potential of genomic medicine is past. Genomics is not tomorrow. It’s here today. Genomics will transform patient outcomes and healthcare systems – and Genomics England is already moving to make a mainstream genomics medicine service a reality in the UK. Realising this potential fully, however, demands more as this transformation can only take place with deep industry partnerships in place. Kick starting a UK genomics industry has been a core Genomics England aim from the outset. It recognises that − whilst NHS England, Genomics England and others build the data resources, infrastructure and systems − it is industry that develops the medicines, treatments and technologies that have such a big impact on patients’ lives. Genomics is made up of many moving parts − from the understanding and consent of the public, to truly pioneering research, to building an effective clinical service. The time for talking about genomic potential is past. The time to talk to business − and forge partnership on an industrial scale – is now.
Director, Biomarkers & Companion Diagnostics
Christophe Le Tourneau
Head, Department of Drug Development & Innovation
Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at the Versailles-Saint-Quentin-en-Yvelines University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 140+ peer-reviewed papers in international journals.
Senior Scientist, Biomarkers
Dr. Orsolya Lorincz graduated as a chemist and received her PhD in biotechnology. She has specialized in the development of nanomedicine formulations, manufacturing technology, and analytical assays. Dr. Lorincz was the head of the Quality Control laboratory of Genetic Immunity between 2010 and 2013. From 2013, as a co-founder of Treos Bio, she is involved in the development and validation of the diagnostic tests, vaccine design and development and supports the chemistry, manufacturing and control activities of the company’s peptide based personal vaccines.
Director General, Post-Authorization
CSO & CEO
Senior Vice President, Commercial Operations
Hans Christian Barre Pedersen
Business Development Manager
Clinical Senior Lecturer, Consultant Upper GI & General Surgeon
Imperial College London
Christopher Peters went to medical school in Leeds and after completing basic surgical training moved to Cambridge to carry out a PhD with Professor Rebecca Fitzgerald. During his PhD he developed a four gene signature to predict outcome in oesophageal adenocarcinoma which was validated in 371 independent cases. He also set up the OCCAMS collaboration which went on to be selected to run the International Cancer Genome Consortium's Whole Genome sequencing project in oesophageal adenocarcinoma. OCCAMS has ongoing CRUK funding and has now recruited in excess of 3000 patients. After moving to London to complete his higher surgical training he was appointed as a Clinical Senior Lecturer and Consultant Upper GI surgeon at Imperial College London with a specialist interest in Biomarkers. His academic interest is molecular and clinical predictors of outcome in Oesophageal adenocarcinoma, and in particular developing ways of combining the two to improve stratification of patients. As the Biomarker lead for the NIHR London IVD Co-operative he also has a programme built around trying to better understand which Biomarkers are likely to achieve clinical adoption- aiming to bridge the gap between the millions spent on Biomarker discovery and validation and the handful that achieve clinical success.
Founder & CTO
Senior Director, Companion Diagnostics, Business Development
Global Head, Biomarkers & Clinical Bioanalysis
Vice President, Companion Diagnostics
Innovation & Precision Medicine Lead
Karen joined Innovate UK, part of UK Research and Innovation, in 2017 as Innovation Lead for Precision Medicine. Karen is responsible for delivering the strategy to fund and support UK businesses towards commercial development of Precision Medicine technologies. Innovate UK is a non-departmental public body which is the prime channel through which the Government incentivises innovation in business. Karen has over 20 years of experience in leading collaborative R&D and in the translation of innovation into business opportunity from various technology platforms and therapeutic areas. This includes over 9 years at Pfizer driving the implementation of emerging therapeutics such as RNAi as well as being a founding member of The Research Network Ltd., a virtual drug discovery company. More recently Karen has led multidisciplinary consortia involving Biotech, NHS, and academic stakeholders to develop a robust clinical diagnostic for non-invasive whole-genome profiling of cancerous tumours. With Innovate UK support, multiple opportunities were evaluated for commercialization and integration of the platform into the NHS. Karen holds a PhD in Molecular Genetics and a BSc in Biochemistry & Genetics from the University of Nottingham.
Vice President MHS, Global IVD
Key Account Manager
Director & Head, Clinical Trials Biosample Management
Head, Internal Product Management
Almac Diagnostic Services